GLAXOSMITHKLINE PLC
Insider CIK 1131399 · THRX 10% owner · HTGM 10% owner · FOLD 10% owner · CVRX 10% owner · AGTC 10% owner · OMED 10% owner · LQDA · CCXI 10% owner · CNCE · PATH · GNCA 10% owner · PRNB 10% owner · PGNY 10% owner · TBPH 10% owner · TPTX Director, 10% owner · WVE 10% owner · DBTX Director · CRSP 10% owner · MORF Director · FULC 10% owner · TBIO 10% owner · SPRO 10% owner · BCYC Director, 10% owner · NKTX Director, 10% owner · LYEL 10% owner · PAND Director, 10% owner · HGSI Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences Ltd. | P Buy | 2025-12-11 | 2025-12-15 | 1,470,000 | $19.00 | $27.93M | 18,245,691 | SEC↗ |
| WVE Wave Life Sciences Ltd. | P Buy | 2024-09-27 | 2024-10-01 | 2,791,930 | $8.00 | $22.34M | 16,775,691 | SEC↗ |
| WVE Wave Life Sciences Ltd. | P Buy | 2023-12-07 | 2024-01-30 | 3,300,000 | $5.00 | $16.50M | 13,983,761 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | J Other deriv | 2022-09-16 | 2022-09-20 | 0 | — | $0 | 0 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | J Other | 2022-09-16 | 2022-09-20 | 9,644,807 | $9.75 | $94.04M | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion deriv | 2021-07-02 | 2021-07-06 | 331,399 | — | $0 | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion deriv | 2021-07-02 | 2021-07-06 | 513,312 | — | $0 | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion deriv | 2021-07-02 | 2021-07-06 | 59,527 | — | $0 | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion deriv | 2021-07-02 | 2021-07-06 | 1,081,434 | — | $0 | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion deriv | 2021-07-02 | 2021-07-06 | 10,055,408 | — | $0 | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion deriv | 2021-07-02 | 2021-07-06 | 589,939 | — | $0 | 0 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion | 2021-07-02 | 2021-07-06 | 635,646 | — | $0 | 732,583 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion | 2021-07-02 | 2021-07-06 | 27,345 | — | $0 | 96,937 | SEC↗ |
| CVRX CVRx, Inc. | P Buy | 2021-07-02 | 2021-07-06 | 275,000 | $18.00 | $4.95M | 1,007,583 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion | 2021-07-02 | 2021-07-06 | 8,380 | — | $0 | 69,592 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion | 2021-07-02 | 2021-07-06 | 1,505 | — | $0 | 33,316 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion | 2021-07-02 | 2021-07-06 | 12,979 | — | $0 | 46,295 | SEC↗ |
| CVRX CVRx, Inc. | C Conversion | 2021-07-02 | 2021-07-06 | 14,917 | — | $0 | 61,212 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-23 | 30,253,189 | — | $0 | 0 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | C Conversion | 2021-06-21 | 2021-06-23 | 30,253,189 | — | $0 | 30,253,189 | SEC↗ |
| INVA Innoviva, Inc. | S Sale | 2021-05-20 | 2021-05-24 | 32,005,260 | $12.25 | $392.06M | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion deriv | 2021-02-17 | 2021-02-19 | 1,737,619 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion deriv | 2021-02-17 | 2021-02-19 | 3,125,000 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion deriv | 2021-02-17 | 2021-02-19 | 7,119,850 | — | $0 | 0 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | P Buy | 2021-02-17 | 2021-02-19 | 150,000 | $18.00 | $2.70M | 1,183,663 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion | 2021-02-17 | 2021-02-19 | 458,487 | — | $0 | 458,487 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion | 2021-02-17 | 2021-02-19 | 247,324 | — | $0 | 705,811 | SEC↗ |
| DBTX Decibel Therapeutics, Inc. | C Conversion | 2021-02-17 | 2021-02-19 | 327,852 | — | $0 | 1,033,663 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | P Buy deriv | 2020-07-24 | 2020-07-30 | 1,260,504 | $0.13 | $163.9K | 1,260,504 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | P Buy | 2020-07-24 | 2020-07-30 | 1,260,504 | $2.25 | $2.84M | 4,626,389 | SEC↗ |
| PAND Pandion Therapeutics, Inc. | C Conversion deriv | 2020-07-21 | 2020-07-22 | 1,776,980 | — | $0 | 0 | SEC↗ |
| PAND Pandion Therapeutics, Inc. | C Conversion deriv | 2020-07-21 | 2020-07-22 | 7,846,554 | — | $0 | 0 | SEC↗ |
| PAND Pandion Therapeutics, Inc. | C Conversion | 2020-07-21 | 2020-07-22 | 348,469 | — | $0 | 1,887,193 | SEC↗ |
| PAND Pandion Therapeutics, Inc. | P Buy | 2020-07-21 | 2020-07-22 | 361,111 | $18.00 | $6.50M | 2,248,304 | SEC↗ |
| PAND Pandion Therapeutics, Inc. | C Conversion | 2020-07-21 | 2020-07-22 | 1,538,724 | — | $0 | 1,538,724 | SEC↗ |
| PAND Pandion Therapeutics, Inc. | A Award deriv | 2020-07-17 | 2020-07-22 | 13,997 | — | $0 | 13,997 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | S Sale | 2020-07-15 | 2020-09-18 | 3,069 | $19.40 | $59.5K | 1,910,609 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | S Sale | 2020-07-15 | 2020-09-18 | 78 | $19.25 | $1.5K | 1,910,531 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2020-07-14 | 2020-07-16 | 10,700 | — | $0 | 10,700 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-16 | 292,663 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-16 | 1,994,348 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-16 | 6,337,403 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion | 2020-07-14 | 2020-07-16 | 525,499 | — | $0 | 604,589 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion | 2020-07-14 | 2020-07-16 | 1,712,810 | — | $0 | 2,317,399 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2020-07-14 | 2020-07-16 | 833,333 | $18.00 | $15.00M | 3,150,732 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion | 2020-07-14 | 2020-07-16 | 79,090 | — | $0 | 79,090 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | S Sale | 2020-07-14 | 2020-09-18 | 1,597 | $19.27 | $30.8K | 1,913,678 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | S Sale deriv | 2020-06-22 | 2020-06-22 | 0 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2020-05-21 | 2020-05-26 | 83,333 | $60.00 | $5.00M | 2,253,660 | SEC↗ |
| PGNY Progyny, Inc. | S Sale | 2020-05-20 | 2020-05-21 | 4,000,000 | $25.75 | $103.00M | 6,238,244 | SEC↗ |
| PGNY Progyny, Inc. | C Conversion deriv | 2019-10-29 | 2019-10-31 | 9,821,190 | — | $0 | 0 | SEC↗ |
| PGNY Progyny, Inc. | C Conversion | 2019-10-29 | 2019-10-31 | 9,821,190 | — | $0 | 10,238,244 | SEC↗ |
| PRNB Principia Biopharma Inc. | P Buy | 2019-10-18 | 2019-10-22 | 357,142 | $28.00 | $10.00M | 2,982,855 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2019-09-10 | 2019-09-12 | 177,777 | $45.00 | $8.00M | 2,170,327 | SEC↗ |
| FULC Fulcrum Therapeutics, Inc. | C Conversion deriv | 2019-07-22 | 2019-07-24 | 12,500,000 | — | $0 | 0 | SEC↗ |
| FULC Fulcrum Therapeutics, Inc. | C Conversion | 2019-07-22 | 2019-07-24 | 1,785,714 | — | $0 | 1,785,714 | SEC↗ |
| MORF Morphic Holding, Inc. | C Conversion deriv | 2019-07-01 | 2019-07-02 | 830,489 | — | $0 | 0 | SEC↗ |
| MORF Morphic Holding, Inc. | C Conversion deriv | 2019-07-01 | 2019-07-02 | 1,469,950 | — | $0 | 0 | SEC↗ |
| MORF Morphic Holding, Inc. | C Conversion | 2019-07-01 | 2019-07-02 | 830,489 | — | $0 | 2,300,439 | SEC↗ |
| MORF Morphic Holding, Inc. | P Buy | 2019-07-01 | 2019-07-02 | 333,333 | $15.00 | $5.00M | 2,633,772 | SEC↗ |
| MORF Morphic Holding, Inc. | C Conversion | 2019-07-01 | 2019-07-02 | 1,469,950 | — | $0 | 1,469,950 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | P Buy | 2019-06-24 | 2019-06-26 | 1,857,142 | $3.50 | $6.50M | 3,365,884 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2019-06-11 | 2019-06-17 | 10,240 | — | $0 | 10,240 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | C Conversion deriv | 2019-05-28 | 2019-05-30 | 445,323 | — | $0 | 0 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | C Conversion deriv | 2019-05-28 | 2019-05-30 | 625,049 | — | $0 | 0 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | C Conversion | 2019-05-28 | 2019-05-30 | 636,366 | — | $0 | 1,529,561 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | P Buy | 2019-05-28 | 2019-05-30 | 385,714 | $14.00 | $5.40M | 1,915,275 | SEC↗ |
| BCYC BICYCLE THERAPEUTICS plc | C Conversion | 2019-05-28 | 2019-05-30 | 893,195 | — | $0 | 893,195 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion deriv | 2019-04-22 | 2019-04-24 | 4,314,809 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2019-04-22 | 2019-04-24 | 15,000 | — | $0 | 15,000 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion deriv | 2019-04-22 | 2019-04-24 | 2,105,259 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion | 2019-04-22 | 2019-04-24 | 546,820 | — | $0 | 1,667,550 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2019-04-22 | 2019-04-24 | 325,000 | $18.00 | $5.85M | 1,992,550 | SEC↗ |
| TPTX Turning Point Therapeutics | C Conversion | 2019-04-22 | 2019-04-24 | 1,120,730 | — | $0 | 1,120,730 | SEC↗ |
| CCXI ChemoCentryx, Inc. | S Sale | 2018-10-16 | 2018-10-18 | 7,343,492 | $11.69 | $85.85M | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 9,726,783 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 2,840,909 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 4,942,070 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,521,895 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion deriv | 2018-09-18 | 2018-09-20 | 2,367,424 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 2,355,713 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| PRNB Principia Biopharma Inc. | P Buy | 2018-09-18 | 2018-09-20 | 270,000 | $17.00 | $4.59M | 2,625,713 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| PRNB Principia Biopharma Inc. | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2018-09-13 | 2019-01-15 | 20,475 | — | $0 | 20,475 | SEC↗ |
| LQDA Liquidia Technologies Inc | C Conversion deriv | 2018-07-30 | 2018-08-01 | 344,853 | — | $0 | 0 | SEC↗ |
| LQDA Liquidia Technologies Inc | C Conversion deriv | 2018-07-30 | 2018-08-01 | 4,765,248 | — | $0 | 0 | SEC↗ |
| LQDA Liquidia Technologies Inc | C Conversion | 2018-07-30 | 2018-08-01 | 118,570 | — | $0 | 475,604 | SEC↗ |
| LQDA Liquidia Technologies Inc | C Conversion | 2018-07-30 | 2018-08-01 | 336,541 | — | $0 | 475,604 | SEC↗ |
| LQDA Liquidia Technologies Inc | P Buy | 2018-07-30 | 2018-08-01 | 148,818 | $11.00 | $1.64M | 624,422 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | P Buy | 2018-07-17 | 2018-07-17 | 80,000 | $12.50 | $1.00M | 1,934,006 | SEC↗ |
| TBIO Translate Bio, Inc. | C Conversion deriv | 2018-07-02 | 2018-07-03 | 7,222,797 | — | $0 | 0 | SEC↗ |
| TBIO Translate Bio, Inc. | C Conversion deriv | 2018-07-02 | 2018-07-03 | 2,525,253 | — | $0 | 0 | SEC↗ |
| TBIO Translate Bio, Inc. | C Conversion deriv | 2018-07-02 | 2018-07-03 | 9,300,000 | — | $0 | 0 | SEC↗ |
| TBIO Translate Bio, Inc. | C Conversion | 2018-07-02 | 2018-07-03 | 1,674,016 | — | $0 | 1,674,016 | SEC↗ |
| TBIO Translate Bio, Inc. | C Conversion | 2018-07-02 | 2018-07-03 | 454,550 | — | $0 | 3,428,682 | SEC↗ |
| TBIO Translate Bio, Inc. | P Buy | 2018-07-02 | 2018-07-03 | 269,230 | $13.00 | $3.50M | 3,697,912 | SEC↗ |
| TBIO Translate Bio, Inc. | C Conversion | 2018-07-02 | 2018-07-03 | 1,300,116 | — | $0 | 2,974,132 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion deriv | 2017-11-06 | 2017-11-07 | 1,483,784 | — | $0 | 0 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion deriv | 2017-11-06 | 2017-11-07 | 982,906 | — | $0 | 0 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion deriv | 2017-11-06 | 2017-11-07 | 1,250,000 | — | $0 | 0 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion deriv | 2017-11-06 | 2017-11-07 | 3,683,045 | — | $0 | 0 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion | 2017-11-06 | 2017-11-07 | 606,024 | — | $0 | 1,425,435 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion | 2017-11-06 | 2017-11-07 | 244,147 | — | $0 | 244,147 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion | 2017-11-06 | 2017-11-07 | 246,272 | — | $0 | 490,419 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | C Conversion | 2017-11-06 | 2017-11-07 | 328,992 | — | $0 | 819,411 | SEC↗ |
| SPRO Spero Therapeutics, Inc. | P Buy | 2017-11-06 | 2017-11-07 | 428,571 | $14.00 | $6.00M | 1,854,006 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-03-27 | 2017-03-29 | 300,000 | $10.15 | $3.04M | 792,781 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | S Sale | 2017-03-27 | 2017-03-30 | 300,000 | $10.15 | $3.04M | 792,781 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-10-26 | 211,567 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion deriv | 2016-10-24 | 2016-10-26 | 2,942,560 | — | $0 | 0 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-10-26 | 2,942,560 | — | $0 | 2,942,560 | SEC↗ |
| CRSP CRISPR Therapeutics AG | P Buy | 2016-10-24 | 2016-10-26 | 66,500 | $14.00 | $931.0K | 3,220,627 | SEC↗ |
| CRSP CRISPR Therapeutics AG | C Conversion | 2016-10-24 | 2016-10-26 | 211,567 | — | $0 | 3,154,127 | SEC↗ |
| CRSP CRISPR Therapeutics AG | A Award deriv | 2016-10-18 | 2016-10-20 | 30,000 | — | $0 | 30,000 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | P Buy | 2016-03-14 | 2016-03-15 | 1,301,015 | $23027965.50 | $29959.73B | 9,644,807 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | P Buy | 2015-10-07 | 2015-10-07 | 44,574 | $607543.62 | $27.08B | 8,343,792 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2015-08-07 | 2015-08-07 | 245,828 | $3485841.04 | $856.92B | 32,005,260 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-13 | 2,784,593 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-13 | 36,546,366 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-13 | 15,227,653 | — | $0 | 0 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-13 | 43,538 | — | $0 | 43,538 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion deriv | 2015-05-11 | 2015-05-13 | 110,755 | — | $0 | 0 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2015-05-11 | 2015-05-11 | 85,579 | $1369264.00 | $117.18B | 31,759,432 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion | 2015-05-11 | 2015-05-13 | 340,314 | — | $0 | 705,420 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion | 2015-05-11 | 2015-05-13 | 110,755 | — | $0 | 1,049,243 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | J Other | 2015-05-11 | 2015-05-13 | 91,271 | — | $0 | 938,488 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | C Conversion | 2015-05-11 | 2015-05-13 | 141,797 | — | $0 | 847,217 | SEC↗ |
| HTGM HTG MOLECULAR DIAGNOSTICS, | P Buy | 2015-05-11 | 2015-05-13 | 365,106 | $14.00 | $5.11M | 365,106 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2015-03-02 | 2015-03-02 | 92,674 | $1673692.44 | $155.11B | 31,673,853 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | S Sale | 2015-02-23 | 2015-02-24 | 503,150 | $22.00 | $11.07M | 1,436,448 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | S Sale | 2014-12-18 | 2015-02-12 | 12,000 | $21.01 | $252.1K | 1,939,598 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | S Sale | 2014-12-17 | 2015-02-12 | 8,000 | $21.00 | $168.0K | 1,951,598 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | S Sale | 2014-12-12 | 2015-02-12 | 7,500 | $21.24 | $159.3K | 1,959,598 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | S Sale | 2014-12-11 | 2015-02-12 | 12,500 | $21.28 | $266.0K | 1,967,098 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | S Sale | 2014-12-10 | 2015-02-12 | 10,000 | $21.18 | $211.8K | 1,979,598 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2014-11-04 | 2014-11-04 | 832,456 | $12786524.16 | $10644.22B | 31,581,179 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | S Sale | 2014-10-27 | 2014-10-28 | 11,315,825 | $5.29 | $59.86M | 0 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2014-08-11 | 2014-08-11 | 172,651 | $3912271.66 | $675.46B | 30,748,723 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | J Other deriv | 2014-06-02 | 2014-06-04 | 436,802 | — | $0 | 436,802 | SEC↗ |
| TBPH Theravance Biopharma, Inc. | J Other | 2014-06-02 | 2014-06-04 | 436,802 | — | $0 | 8,299,218 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2014-05-09 | 2014-05-13 | 317,770 | $8544835.30 | $2715.29B | 30,576,072 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | C Conversion deriv | 2014-04-01 | 2014-04-02 | 17,625,289 | — | $0 | 0 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | C Conversion deriv | 2014-04-01 | 2014-04-02 | 15,671,969 | — | $0 | 0 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | C Conversion deriv | 2014-04-01 | 2014-04-02 | 32,707,070 | — | $0 | 0 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | C Conversion | 2014-04-01 | 2014-04-02 | 1,885,836 | — | $0 | 1,885,836 | SEC↗ |
| AGTC APPLIED GENETIC TECHNOLOGI | P Buy | 2014-04-01 | 2014-04-02 | 103,762 | $12.00 | $1.25M | 1,989,598 | SEC↗ |
| PATH NUPATHE INC. | J Other deriv | 2014-02-21 | 2014-02-24 | 15,635 | — | $0 | 0 | SEC↗ |
| PATH NUPATHE INC. | U Tender | 2014-02-21 | 2014-02-24 | 4,168,017 | — | $0 | 0 | SEC↗ |
| CNCE CONCERT PHARMACEUTICALS, I | C Conversion deriv | 2014-02-19 | 2014-02-20 | 800,000 | — | $0 | 0 | SEC↗ |
| CNCE CONCERT PHARMACEUTICALS, I | C Conversion deriv | 2014-02-19 | 2014-02-20 | 6,666,667 | — | $0 | 0 | SEC↗ |
| CNCE CONCERT PHARMACEUTICALS, I | C Conversion | 2014-02-19 | 2014-02-20 | 141,592 | — | $0 | 141,592 | SEC↗ |
| CNCE CONCERT PHARMACEUTICALS, I | P Buy | 2014-02-19 | 2014-02-20 | 35,000 | $14.00 | $490.0K | 1,356,533 | SEC↗ |
| CNCE CONCERT PHARMACEUTICALS, I | C Conversion | 2014-02-19 | 2014-02-20 | 1,179,941 | — | $0 | 1,321,533 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2014-02-11 | 2014-02-13 | 342,229 | $12850698.95 | $4397.88B | 30,258,302 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion deriv | 2014-02-10 | 2014-02-12 | 4,851,958 | — | $0 | 0 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion deriv | 2014-02-10 | 2014-02-12 | 4,099,231 | — | $0 | 0 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion deriv | 2014-02-10 | 2014-02-12 | 9,230,769 | — | $0 | 0 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion | 2014-02-10 | 2014-02-12 | 775,694 | — | $0 | 919,467 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | P Buy | 2014-02-10 | 2014-02-12 | 143,773 | $12.00 | $1.73M | 143,773 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion | 2014-02-10 | 2014-02-12 | 407,727 | — | $0 | 1,671,667 | SEC↗ |
| GNCA GENOCEA BIOSCIENCES, INC. | C Conversion | 2014-02-10 | 2014-02-12 | 344,473 | — | $0 | 1,263,940 | SEC↗ |
| PATH NUPATHE INC. | C Conversion deriv | 2014-02-06 | 2014-02-24 | 1,500,000 | — | $0 | 0 | SEC↗ |
| PATH NUPATHE INC. | C Conversion | 2014-02-06 | 2014-02-24 | 1,500,000 | $2.00 | $3.00M | 4,168,017 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | P Buy | 2013-11-20 | 2013-11-22 | 1,500,000 | $2.00 | $3.00M | 11,315,825 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2013-10-29 | 2013-10-29 | 130,473 | $4913613.18 | $641.09B | 29,916,073 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2013-07-30 | 2013-08-01 | 3,064,407 | $111850855.50 | $342756.54B | 29,785,600 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion deriv | 2013-07-23 | 2013-07-23 | 1,441,396 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion deriv | 2013-07-23 | 2013-07-23 | 1,166,150 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion | 2013-07-23 | 2013-07-23 | 1,441,396 | — | $0 | 1,441,396 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion | 2013-07-23 | 2013-07-23 | 1,166,150 | — | $0 | 2,607,546 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2013-04-30 | 2013-04-30 | 193,563 | $6699215.43 | $1296.72B | 26,721,193 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2013-02-15 | 2013-02-20 | 116,527 | $2567089.81 | $299.14B | 26,527,630 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2012-11-02 | 2012-11-05 | 280,348 | $6265777.80 | $1756.60B | 26,411,103 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2012-08-03 | 2012-08-07 | 316,334 | $28.21 | $8.92M | 26,130,755 | SEC↗ |
| HGSI HUMAN GENOME SCIENCES INC | P Buy | 2012-08-02 | 2012-08-03 | 59,232,487 | $14.25 | $844.06M | 233,716,708 | SEC↗ |
| HGSI HUMAN GENOME SCIENCES INC | P Buy | 2012-08-02 | 2012-08-03 | 3,413,699 | $14.25 | $48.65M | 174,484,221 | SEC↗ |
| HGSI HUMAN GENOME SCIENCES INC | P Buy | 2012-08-01 | 2012-08-01 | 1,788,186 | $14.25 | $25.48M | 165,383,807 | SEC↗ |
| HGSI HUMAN GENOME SCIENCES INC | P Buy | 2012-08-01 | 2012-08-03 | 5,686,715 | $14.25 | $81.04M | 171,070,522 | SEC↗ |
| HGSI HUMAN GENOME SCIENCES INC | P Buy | 2012-07-30 | 2012-08-01 | 4,934,743 | $14.25 | $70.32M | 163,595,621 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | P Buy | 2012-07-17 | 2012-07-17 | 2,949,581 | $6.30 | $18.58M | 9,815,825 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2012-05-16 | 2012-05-16 | 10,000,000 | $21.29 | $212.90M | 25,814,421 | SEC↗ |
| THRX THERAVANCE INC | P Buy | 2012-02-14 | 2012-02-14 | 88,468 | $18.12 | $1.60M | 15,814,421 | SEC↗ |
| CCXI ChemoCentryx, Inc. | C Conversion deriv | 2012-02-13 | 2012-02-15 | 6,793,478 | — | $0 | 0 | SEC↗ |
| CCXI ChemoCentryx, Inc. | C Conversion deriv | 2012-02-13 | 2012-02-15 | 6,493,506 | — | $0 | 0 | SEC↗ |
| CCXI ChemoCentryx, Inc. | C Conversion | 2012-02-13 | 2012-02-15 | 3,246,753 | — | $0 | 3,946,753 | SEC↗ |
| CCXI ChemoCentryx, Inc. | C Conversion | 2012-02-13 | 2012-02-15 | 3,396,739 | — | $0 | 7,343,492 | SEC↗ |